ClinicalTrials.gg
RecruitingNCT05648474Updated Oct 24, 2024

Intraoperative Monitoring for the Lateral Lumbar Interbody Fusion Procedure

An observational study in Intervertebral Disc Degeneration, Stenosis, Spinal and Spondylolisthesis, sponsored by Alphatec Spine, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Alphatec Spine, Inc. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Planned enrollment
10th of 91
400 · median 118
Started
2022
with 14 others
Observational
91 of 232
19 open now
Primary completion
2025-08
later than 8 of 57 live
Registered
200th of 232
by date
Lead sponsor
4 of 232
Alphatec Spine, Inc.

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 10th largest by planned enrollment of the 91 observational ones that give a count, is one of 15 that started in 2022, is one of 91 observational ones, reaches primary completion later than 8 of the 57 other live ones, and was the 200th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the clinical utility of a known intraoperative neuromonitoring modality (SSEP) using saphenous nerve as the site of stimulation to identify changes to the lumbar nerves which may be at risk during the lateral lumbar interbody fusion (LLIF) procedure.

03

Conditions studied

  • Intervertebral Disc Degeneration
  • Stenosis, Spinal
  • Spondylolisthesis
  • Spinal Deformity
  • Spinal Instability

Keywords

  • Spine
  • Surgery
  • Adult
  • Neuromonitoring
  • Electromyography
  • Somatosensory evoked potentials
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients of both sexes undergoing LLIF surgery atone or two levels inclusive of the L4-5 level.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age at the time of planned surgery.
  • Indicated for 1- or 2-level instrumented LLIF surgery (in either prone or lateral decubitus positions), inclusive of the L4-5 disc space.
  • Written obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients requiring surgical treatment at more than 2 lumbar levels.
  • Patients with peripheral neuropathy such as from diabetes or other conditions that might affect the reliability of intraoperative neuromonitoring.
  • Patients with prior history of partial/full hip or knee joint replacement surgery (i.e., arthroplasty or resurfacing) on the leg targeted for saphenous monitoring and electrode placement.
  • Patients with presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • Female patients who are pregnant or wanting to become pregnant during the timeframe of study participation.
  • Patients participating in another clinical study which may compromise this study's results or compliance with this study's procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult undergoing 1- or 2-level lateral lumbar interbody fusion surgery, inclusive of the L4-5 level

    Diagnostic Test: Somatosensory evoked potential [SSEP] intraoperative monitoring

Interventions

  • Diagnostic testSomatosensory evoked potential [SSEP] intraoperative monitoring

    No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery

06

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of SSEP neuromonitoring in post-operative clinical diagnosis of motor/sensory deficits

    This outcome measure determines the utility of the saphenous nerve SSEP monitoring based on the correlation of intraoperative neuromonitoring results with new or worsened postoperative neural deficits, as measured by motor and sensory physical exam.

    Time frame: 6 weeks or until new or worsened neural deficits are resolved, but not exceeding 12 months.

Secondary outcomes

  1. Determination of the positive predictive value (PPV) and negative predictive value (NPV) of free run and SSEP monitoring modalities.

    This outcome measure includes: * Correlating specific monitoring findings with incidence of new or worsened motor or sensory deficits post-operatively and their correlation with patient-specific and surgical factors. * Correlating patient and surgical factors with new and worsened postoperative neural deficits.

    Time frame: 6 weeks or until new or worsened neural deficits are resolved, but not exceeding 12 months.

07

Study locations

1 of 1 sites recruiting
  • Alphatec Spine Inc.
    Carlsbad, California 92008, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Aug 2025, 37 months after the start.

Of 80 observational studies under Intervertebral Disc Degeneration, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 84. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 13, 2022
StartActual
Jul 13, 2022
Primary completionEst.
Aug 28, 2025
CompletionEst.
Dec 31, 2025
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05648474
Lead sponsor
Alphatec Spine, Inc.
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
Jul 13, 2022
Primary completion
Aug 28, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Oct 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion